Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 18, 2024
Product Development
Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report
Plus: Readouts from Sanofi-Teva, Bicycle and more
BioCentury | Apr 25, 2023
Data Byte
Aggressive cuts part of Novartis’ focus on higher-potential pipeline
The pharma’s latest quarterly update revealed a pruning of 10% of its pipeline, including several early-stage cancer programs
BioCentury | Dec 19, 2022
Product Development
Arcus’ TIGIT data don’t provide hoped for differentiation
Domvanalimab/PD-1 combo doesn’t stack up to Roche combo, which missed Phase III endpoint
BioCentury | May 25, 2022
Finance
With shares suspended, CStone board readies to meet
Once on a fast track to become a bellwether, China biotech has found itself in limbo
BioCentury | Nov 19, 2021
Deals
Momentum for TIGIT, adenosine with Gilead’s grab of Arcus options
While disclosed data remain limited, Gilead highlights potential for combos
BioCentury | Nov 13, 2021
Data Byte
CHMP opinions for November include KRAS inhibitor sotorasib
Two new COVID-19 mAbs among recommended
BioCentury | Oct 21, 2021
Emerging Company Profile
Elpiscience builds out global pipeline with CD39 focus
Dual-track strategy includes in-licensing for China market, but focus is on driving wholly-owned pipeline in U.S.
BioCentury | Jul 24, 2021
Regulation
July CHMP recommendations: Data Byte
Among CHMP’s positive opinions this month is a recommendation for Nexviadyme avalglucosidase alfa, a long-term recombinant human GAA replacement therapy by the Genzyme unit of Sanofi
BioCentury | Jun 14, 2021
Deals
GSK fuels TIGIT frenzy with $625M payout for iTeos’ mAb
iTeos’ Phase I anti-TIGIT mAb draws one of the largest-ever immuno-oncology deals
BioCentury | May 20, 2021
Product Development
Adenosine pathway inhibitors at ASCO21: Data Byte
Adenosine pathway inhibitors from I-Mab and Arcus showed higher response rates than competitors at ASCO21. Extracellular adenosine dampens antitumor immunity by interacting with adenosine receptors on
Items per page:
1 - 10 of 270